Press release
Advanced Kidney Cancer FDA Approvals, Drugs, Pipeline Outlook 2024 | Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics
DelveInsight's, "Advanced Kidney Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Kidney Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Advanced Kidney Cancer research. Learn more about our innovative pipeline today! @ Advanced Kidney Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Advanced Kidney Cancer Pipeline Report
• June 2024:- Michael B. Atkins, MD- This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B.
• June 2024:- Eisai Inc.- The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review [IIR] using Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
• June 2024:- Hoffmann-La Roche- This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
• June 2024:- Ipsen- The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
• June 2024:- Incyte Corporation- A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive. This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
• DelveInsight's Advanced Kidney Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Advanced Kidney Cancer treatment.
• The leading Advanced Kidney Cancer Companies such as Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others.
• Promising Advanced Kidney Cancer Therapies such as HB0025, Ipilimumab, Nivolumab, Belzutifan, Botensilimab, Balstilimab, Ipilimumab, ST-1898 tablets, Everolimus, and others.
Stay informed about the cutting-edge advancements in Advanced Kidney Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Kidney Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Kidney Cancer Emerging Drugs Profile
• Savolitinib: AstraZeneca
Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.
• Relatlimab: Bristol-Myers Squibb
Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.
• JANX008: Janux Therapeutics
JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). The drug is currently being evaluated under Phase I clinical trial for the treatment of Advanced Kidney Cancer.
Learn more about Advanced Kidney Cancer Drugs opportunities in our groundbreaking Advanced Kidney Cancer research and development projects @ Advanced Kidney Cancer Unmet Needs- https://www.delveinsight.com/sample-request/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Kidney Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Advanced Kidney Cancer Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Discover the latest advancements in Advanced Kidney Cancer treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Kidney Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Advanced Kidney Cancer Pipeline Report
• Coverage- Global
• Advanced Kidney Cancer Companies- Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others.
• Advanced Kidney Cancer Therapies- HB0025, Ipilimumab, Nivolumab, Belzutifan, Botensilimab, Balstilimab, Ipilimumab, ST-1898 tablets, Everolimus, and others.
• Advanced Kidney Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Kidney Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Kidney Cancer pipeline on our website @ Advanced Kidney Cancer Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Advanced Kidney Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Kidney Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Savolitinib: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Relatlimab: Bristol-Myers Squibb
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. JANX008: Janux Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Kidney Cancer Key Companies
21. Advanced Kidney Cancer Key Products
22. Advanced Kidney Cancer- Unmet Needs
23. Advanced Kidney Cancer- Market Drivers and Barriers
24. Advanced Kidney Cancer- Future Perspectives and Conclusion
25. Advanced Kidney Cancer Analyst Views
26. Advanced Kidney Cancer Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2024
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Chronic Neuropathic Pain Market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Cancer Therapy Market- https://www.delveinsight.com/report-store/cancer-therapy-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Methicillin-resistant Staphylococcus Aureus Mrsa Infection Market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
Glioblastoma Multiforme Market- https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Polycystic Ovarian Syndrome Market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
Rhinosinusitis Market- https://www.delveinsight.com/report-store/rhinosinusitis-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Wilms Tumor Market- https://www.delveinsight.com/report-store/wilms-tumor-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Venous Thromboembolism Market- https://www.delveinsight.com/report-store/venous-thromboembolism-market
Beta Thalassemia Market- https://www.delveinsight.com/report-store/beta-thalassemia-market
Cold Agglutinin Disease Market- https://www.delveinsight.com/report-store/cold-agglutinin-disease-cad-market
Postpartum Depression Market- https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Radiation Dermatitis Market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
Synovial Sarcoma Market- https://www.delveinsight.com/report-store/synovial-sarcoma-market
Tendinopathy Market- https://www.delveinsight.com/report-store/tendinopathy-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Diabetic Nephropathy Market- https://www.delveinsight.com/report-store/diabetic-nephropathy-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Pcsk9 Inhibitors Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-market
Respiratory Syncytial Virus Market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Chemotherapy Induced Neutropenia Market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Glioblastoma Multiforme Market- https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Primary Biliary Cholangitis Market- https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market
Membranous Nephropathy Market- https://www.delveinsight.com/report-store/membranous-nephropathy-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Post Operative Pain Market- https://www.delveinsight.com/report-store/postoperative-pain-market
Genital Herpes Market- https://www.delveinsight.com/report-store/genital-herpes-market
Axillary Hyperhidrosis Market- https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Kidney Cancer FDA Approvals, Drugs, Pipeline Outlook 2024 | Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics here
News-ID: 3577598 • Views: …
More Releases from DelveInsight Business Research LLP
![Adrenal Crisis Market to Grow Positively at a Significant CAGR, asserts DelveInsight | Antares Pharma, Eton Pharmaceuticals, and others](https://cdn.open-pr.com/L/8/L822431992_g.jpg)
Adrenal Crisis Market to Grow Positively at a Significant CAGR, asserts DelveIns …
DelveInsight's "Adrenal Crisis - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Adrenal Crisis market share of the individual therapies, current and forecasted Adrenal Crisis market size from 2020 to 2034 segmented by seven major markets. The report also offers current Adrenal Crisis therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the…
![Sarcopenia Market to Grow Positively at a Paltry CAGR During the Study Period (2020-2034) | Biophytis, Rejuvenate Biomed, Lipocine Inc, and others](https://cdn.open-pr.com/L/8/L822305167_g.jpg)
Sarcopenia Market to Grow Positively at a Paltry CAGR During the Study Period (2 …
DelveInsight's "Sarcopenia - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Sarcopenia market share of the individual therapies, current and forecasted Sarcopenia market size from 2020 to 2034 segmented by seven major markets. The report also offers current Sarcopenia therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the…
![Autosomal Dominant Polycystic Kidney Disease Market to Grow Positively at a Paltry CAGR During the Study Period | Otsuka Pharmaceutical, Sanofi, Regulus Therapeutics, and others](https://cdn.open-pr.com/L/8/L822245679_g.jpg)
Autosomal Dominant Polycystic Kidney Disease Market to Grow Positively at a Palt …
DelveInsight's "Autosomal Dominant Polycystic Kidney Disease - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Autosomal Dominant Polycystic Kidney Disease market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease market size from 2020 to 2034 segmented by seven major markets. The report also offers current Autosomal Dominant Polycystic Kidney Disease therapy algorithms, market drivers, market barriers, and unmet…
![Adenoid Cystic Carcinoma Market to Grow Positively at a Paltry CAGR During the Study Period (2019-2032) | Merck, Ayala Pharmaceuticals, and others](https://cdn.open-pr.com/L/8/L822972445_g.jpg)
Adenoid Cystic Carcinoma Market to Grow Positively at a Paltry CAGR During the S …
DelveInsight's "Adenoid Cystic Carcinoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Adenoid Cystic Carcinoma market share of the individual therapies, current and forecasted Adenoid Cystic Carcinoma market size from 2019 to 2032 segmented by seven major markets. The report also offers current Adenoid Cystic Carcinoma therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview
Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports.
This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top…